Compound heterozygous RAG2 mutations mimicking hyper IgM syndrome.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. Rheumatologic and Autoimmune Features of Inborn Errors of Immunity: Implications for Diagnosis and Management.Journal of human immunity · 2025
   Article
2. Hypomorphic RAG2 Deficiency Promotes Selection of Self-Reactive B Cells.Journal of clinical immunology · 2025
   Article
3. Predicting the Occurrence of Variants in RAG1 and RAG2.Journal of clinical immunology · 2019
   Article
4. Biological Characteristics of Severe Combined Immunodeficient Mice Produced by CRISPR/Cas9-MediatedFrontiers in genetics · 2019
   Article

Corrections and comments

• Comment on
  A novel homozygous mutation in recombination activating gene 2 in 2 relatives with different clinical phenotypes: Omenn syndrome and hyper-IgM syndrome.2012

Authors and funding

8 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as